Open access
Open access
Powered by Google Translator Translator

Internal Medicine

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.

16 Nov, 2021 | 08:41h | UTC

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used.

16 Nov, 2021 | 08:39h | UTC

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

16 Nov, 2021 | 08:37h | UTC

2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Neonatal Life Support; Education, Implementation, and Teams; First Aid Task Forces; and the COVID-19 Working Group – Circulation (for an HTML version click here)

Top Things to Know: International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations (CoSTR) – American Heart Association

 

#AHA21 – [News release – not published yet] RCT: Long-term, low-dose aspirin did not affect risk of dementia in adults with type 2 diabetes.

16 Nov, 2021 | 08:30h | UTC

Long-term, low-dose aspirin did not affect risk of dementia in adults with type 2 diabetes – American Heart Association

Original Study: Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

 

#AHA21 – Among patients with intermittent atrial fibrillation, n-of-1 trials with 466 patients found alcohol, but not caffeine, increased the risk of atrial fibrillation events.

16 Nov, 2021 | 08:29h | UTC

Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation: The I-STOP-AFib Randomized Clinical Trial – JAMA Cardiology (free for a limited period)

Commentary: Avoiding AF Triggers Doesn’t Improve Quality of Life: I-STOP-AFib – TCTMD

 

Commentary on Twitter

 

Systematic Review: Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

16 Nov, 2021 | 08:25h | UTC

Summary: Immunosuppressive treatment for adults with idiopathic membranous nephropathy – Cochrane Library

Original Study: Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome – Cochrane Library

 

Review | Glycemic management in diabetes: old and new approaches.

16 Nov, 2021 | 08:17h | UTC

Glycaemic management in diabetes: old and new approaches – The Lancet Diabetes & Endocrinology (free registration required)

 

Commentary on Twitter

 

Podcast | Obstetrics for the Internist: What to Expect.

16 Nov, 2021 | 08:18h | UTC

#305 OB for the Internist: What to Expect – The Curbsiders

 

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

 

#AHA21 – RCT: Among children and adolescents who had screening echocardiograms and were identified as having latent rheumatic heart disease, secondary antibiotic prophylaxis with penicillin G benzathine for 2 years was associated with reduced echocardiographic progression (0.8 vs. 8.2% in the control group).

14 Nov, 2021 | 20:03h | UTC

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Penicillin significantly reduces rheumatic heart disease progression in children – Murdoch Children’s Research Institute

Penicillin slows devastating impacts of rheumatic heart disease in children from Uganda – Children’s National Hospital

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – American College of Cardiology

 

Commentaries on Twitter

 

#AHA21 – Pooled data from six prospective cohorts found higher sodium and lower potassium intakes were associated in a dose–response manner with a higher cardiovascular risk.

14 Nov, 2021 | 19:58h | UTC

24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Less sodium and more potassium could be key in lowering risk of cardiovascular disease – The Harvard Gazette

Related study: Cohort Study: Joint Association of Urinary Sodium and Potassium Excretion with Cardiovascular Events and Mortality

 

Commentary on Twitter

 

#AHA21 – RCT: In asymptomatic patients with severe aortic stenosis, early surgery improved outcomes compared to conservative treatment.

14 Nov, 2021 | 20:01h | UTC

Aortic Valve ReplAcemenT versus Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis: The AVATAR Trial – Circulation (free for a limited period)

News release: Surgery to replace heart valve beneficial even with no symptoms of severe aortic stenosis – American Heart Association

Commentaries:

AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients – TCTMD

Aortic Valve ReplAcemenT versus Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis – AVATAR – American College of Cardiology

Related study: #AHA19 – Randomized Trial: Early Surgery Improves Outcomes in Asymptomatic Patients with Very Severe Aortic Stenosis

 

Commentary on Twitter

 

Viewpoint | How to Measure Progress in Addressing Physician Well-being: Beyond Burnout.

14 Nov, 2021 | 19:40h | UTC

How to Measure Progress in Addressing Physician Well-being: Beyond Burnout – JAMA

Related:

Physician Well-being 2.0: Where Are We and Where Are We Going?

Consensus Study – Taking Action Against Clinician Burnout: A Systems Approach to Professional Well-Being – National Academies of Medicine

[Abstract Only] Assessment of Risk Factors for Suicide Among US Health Care Professionals

Beyond Burnout: Docs Decry ‘Moral Injury’ From Financial Pressures of Health Care

Perspective: Hospital Administration Response to Physician Stress and Burnout

Opinion: It’s Time to Talk About Physician Burnout and Moral Injury

Systematic Review: Effect of Organization-Directed Workplace Interventions on Physician Burnout

Perspective: The 3 Causes Of Physician Burnout (And Why There’s No Simple Solution)

Physician Burnout: A Global Crisis (several resources on the subject)

 

Observational Study: In patients with shockable in-hospital cardiac arrest, epinephrine before defibrillation was associated with worse survival.

14 Nov, 2021 | 19:33h | UTC

Epinephrine before defibrillation in patients with shockable in-hospital cardiac arrest: propensity matched analysis – The BMJ

 

Commentary on Twitter

 

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method.

12 Nov, 2021 | 10:41h | UTC

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method – The Lancet Infectious Diseases

 

Commentary from the author on Twitter (thread – click for more)

 

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

12 Nov, 2021 | 10:32h | UTC

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID – The Lancet

Related:

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Boosting immunity to COVID-19 vaccines – “New studies highlight the immunological benefits of COVID-19 vaccine boosters, but questions remain over how to best make use of a limited global supply”.

12 Nov, 2021 | 10:37h | UTC

Boosting immunity to COVID-19 vaccines – Nature Medicine

 

EMA Recommendation: Dapagliflozin 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus due to increased risk of diabetic ketoacidosis.

12 Nov, 2021 | 10:28h | UTC

Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus – European Medicines Agency

 

Cohort study: In patients with nonalcoholic steatohepatitis and obesity, bariatric surgery was associated with lower risk of incident major adverse liver outcomes and major adverse cardiovascular events.

12 Nov, 2021 | 10:24h | UTC

Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis – JAMA (free for a limited period)

Editorial: Bariatric Surgery as a Strategy for Improving Outcomes in Nonalcoholic Steatohepatitis – JAMA (free for a limited period)

 

Commentary on Twitter

 

Cohort study: Among older adults with diabetes who were hospitalized for common medical conditions, intensification of diabetes medications at hospital discharge was associated with an increased short-term risk of severe hypoglycemia events but was not associated with improved glycemic control.

12 Nov, 2021 | 09:51h | UTC

Intensification of Diabetes Medications at Hospital Discharge and Clinical Outcomes in Older Adults in the Veterans Administration Health System – JAMA Network Open

 

Cohort study: After an episode of severe hypoglycemia in older adults with diabetes, sulfonylurea or insulin treatment deintensification occurred in fewer than 50% of episodes.

12 Nov, 2021 | 09:53h | UTC

Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes – JAMA Network Open

 

Commentary on Twitter

 

Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis – “Each day of antibiotic therapy was associated with 4% increased odds of experiencing an adverse event”.

12 Nov, 2021 | 09:47h | UTC

Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis – Clinical Microbiology and Infection

 

Commentary on Twitter

 

White-Coat Hypertension: Pathophysiological and Clinical Aspects.

12 Nov, 2021 | 09:48h | UTC

White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020 – Hypertension (free for a limited period)

 

Podcast | COVID Updates: The Outpatient Edition.

11 Nov, 2021 | 08:57h | UTC

COVID Updates: The Outpatient Edition – The Curbsiders

 

Commentary on Twitter

 

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

11 Nov, 2021 | 08:59h | UTC

COVID antiviral pills: what scientists still want to know – Nature

Related:

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.